Pavmed Series Z Stock Performance
| PAVMZ Stock | USD 0.01 0.01 40.94% |
PAVmed Series holds a performance score of 16 on a scale of zero to a hundred. The firm holds a Beta of -13.72, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning PAVmed Series are expected to decrease by larger amounts. On the other hand, during market turmoil, PAVmed Series is expected to outperform it. Use PAVmed Series sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to analyze future returns on PAVmed Series.
Risk-Adjusted Performance
16 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in PAVmed Series Z are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating primary indicators, PAVmed Series showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 - StockTitan | 10/31/2024 |
2 | Acquisition by Glennon Michael J of 450000 shares of PAVmed Series at 0.48 subject to Rule 16b-3 | 11/26/2024 |
| Begin Period Cash Flow | 39.7 M |
PAVmed |
PAVmed Series Relative Risk vs. Return Landscape
If you would invest 2.59 in PAVmed Series Z on September 15, 2024 and sell it today you would lose (1.09) from holding PAVmed Series Z or give up 42.08% of portfolio value over 90 days. PAVmed Series Z is currently producing 13.8505% returns and takes up 66.4432% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than PAVmed, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
PAVmed Series Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PAVmed Series' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PAVmed Series Z, and traders can use it to determine the average amount a PAVmed Series' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2085
| Best Portfolio | Best Equity | PAVMZ | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 66.44 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.21 actual daily | 16 84% of assets perform better |
Based on monthly moving average PAVmed Series is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PAVmed Series by adding it to a well-diversified portfolio.
PAVmed Series Fundamentals Growth
PAVmed Stock prices reflect investors' perceptions of the future prospects and financial health of PAVmed Series, and PAVmed Series fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PAVmed Stock performance.
| Return On Equity | -13.58 | ||||
| Return On Asset | -0.8 | ||||
| Operating Margin | (13.98) % | ||||
| Revenue | 2.45 M | ||||
| EBITDA | (75.74 M) | ||||
| Net Income | (64.17 M) | ||||
| Total Debt | 48.73 M | ||||
| Book Value Per Share | (6.62) X | ||||
| Cash Flow From Operations | (52.04 M) | ||||
| Total Asset | 33.12 M | ||||
| Retained Earnings | (294.43 M) | ||||
| Working Capital | (29.68 M) | ||||
About PAVmed Series Performance
Evaluating PAVmed Series' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if PAVmed Series has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if PAVmed Series has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 30.64 | 29.11 | |
| Return On Tangible Assets | (2.02) | (2.13) | |
| Return On Capital Employed | 3.27 | 3.10 | |
| Return On Assets | (1.94) | (2.03) | |
| Return On Equity | 1.19 | 1.13 |
Things to note about PAVmed Series Z performance evaluation
Checking the ongoing alerts about PAVmed Series for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PAVmed Series Z help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PAVmed Series Z is way too risky over 90 days horizon | |
| PAVmed Series Z has some characteristics of a very speculative penny stock | |
| PAVmed Series Z appears to be risky and price may revert if volatility continues | |
| PAVmed Series Z has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 2.45 M. Net Loss for the year was (64.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| PAVmed Series generates negative cash flow from operations | |
| PAVmed Series Z has a frail financial position based on the latest SEC disclosures |
- Analyzing PAVmed Series' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PAVmed Series' stock is overvalued or undervalued compared to its peers.
- Examining PAVmed Series' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PAVmed Series' management team can have a significant impact on its success or failure. Reviewing the track record and experience of PAVmed Series' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PAVmed Series' stock. These opinions can provide insight into PAVmed Series' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for PAVmed Stock Analysis
When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.